SPY +0.43%
BND -0.25%
QQQ +0.69%
DIA +0.16%
VNQ -1.39%
GLD -2.95%
BTC -1.18%
AAPL +2.06%
GOOGL +1.23%
NVDA +3.93%
MSFT +3.36%
META +0.38%
AMZN +2.26%
TSLA +0.69%
UBER +0.37%
GS -0.66%
BAC +0.12%
JPM +0.33%
BRK.A +0.14%
COST -1.11%
XOM -0.88%
BABA -1.00%
WMT -1.21%
SPCX +0.96%
DIS -1.41%
F -0.07%
  • Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

Stocks
Hillary Super at the 2025 Victoria's Secret Fashion Show in New York City. John Nacion/Getty Images

Victoria's Secret stock is up almost 300%. Wall St credits the 'Ozempic Economy,' but it's only part of the story

Victoria’s Secret shares have surged nearly 300% over the past year. The company’s stock, now trading under VSXY after a June 2026 ticker change, has climbed to levels investors haven’t seen in years.

There are several factors behind the turnaround, including stronger sales, a revamped brand strategy and a new management team. But Wall Street analysts are also pointing to an unlikely potential beneficiary of the Ozempic era: lingerie.

Advertisement

The theory is part of the broader “Ozempic economy,” in which the rapid growth in use of GLP-1 weight-loss medications such as Ozempic, Wegovy and Zepbound could reshape consumer spending.

Invest smarter with our free newsletter.

By signing up, you accept Moneywise Terms of Use, Subscription Agreement, and Privacy Policy.

As millions of people lose weight while taking these medications, they may need to replace clothing that no longer fits — and the “Ozempic effect” is potentially creating a spending boom. Victoria’s Secret appears to be reaping some of the benefits of that shift.

The “Ozempic effect” could mean a new wardrobe, including lingerie

Changes in body size and shape can require people to replace underwear, bras and other intimate apparel, which is an obvious benefit for lingerie retailers like Victoria’s Secret. Coupled with the fact that losing weight is associated with feeling more sexually attractive, according to Duke University Medical Center researchers, it makes even more sense why Victoria’s Secret is seeing sales skyrocket.

Victoria’s Secret CEO Hillary Super has said the company is watching the impact of GLP-1 medications on its customers. Fortune reported that the retailer was seeing roughly a 3% shift downward in the bra-band and underwear sizes being purchased — something Super linked to people losing weight.

Reuters also recently reported that GLP-1 users are returning to physical stores because changes to their bodies make it more difficult to know what will fit without trying clothes on. A ReturnPro survey additionally found that more than half (58%) of GLP-1 users are spending on premium or higher-priced apparel when they visit physical retail stores.

So someone who loses a significant amount of weight may not just buy one new bra. They could potentially replace an entire drawer of underwear and lingerie — and spend more while doing it.

Must Read

Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.

Ozempic isn’t the only reason Victoria’s Secret stock is soaring

That all said, GLP-1s alone haven’t sent Victoria’s Secret shares up almost 300% over the past year. The company has been undergoing a much broader turnaround.

Under Super, Victoria’s Secret has revived its brand, improving its merchandise and moving away from some of the marketing strategies that had alienated customers previously. And the company has reported substantially stronger financial results because of it.

Advertisement

In its fiscal first quarter, Victoria’s Secret reported $1.56 billion in sales, up 15% from the prior year. Comparable store sales increased 13%, while operating income jumped to $76 million from $20 million a year earlier.

The company has also highlighted its operational and shareholder-performance improvements under its new leadership.

“Since the Board announced Ms. Super’s appointment in August 2024, VS&Co has delivered total shareholder return (“TSR”) of 141%, significantly outperforming the peer group used by research analysts, the S&P 500 Consumer Discretionary Distribution Retail index, and the S&P 600,” the company wrote in a May 2026 letter to shareholders.

Some prominent investors have taken notice. Billionaire hedge fund manager David Einhorn’s firm recently exited its entire Victoria’s Secret position after holding the stock for about a year. The investment generated a reported 157% internal rate of return.

You May Also Like

Share this:
AnnaMarie Houlis Weekend Editor

AnnaMarie Houlis is a journalist and author with more than 15 years of experience, thousands of bylines and four books covering everything from travel, lifestyle and wellness to finance, technology and business.

more from AnnaMarie Houlis

Explore the latest

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither investment, tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities, enter into any loan, mortgage or insurance agreements or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter. Advertisers are not responsible for the content of this site, including any editorials or reviews that may appear on this site. For complete and current information on any advertiser product, please visit their website.

†Terms and Conditions apply.